Abstract
The protonation process of tyrosine kinase inhibitor lapatinib was studied by means of 1HNMR and UV/Vis spectroscopy joint with the theoretical calculations at DFT and semi-empirical levels. DFT/M06-2X geometries were used to describe and compare the different cationic forms of lapatinib, while ZINDO/S-CI method performed on those geometries allowed for the interpretation of experimental UV/Vis spectra of lapatinib at various pH. We found that at low pH two different dicationic forms (N2N1 and N1N3) of lapatinib were present in ethanol and DMSO-d6 solutions. The first protonation, however, occurred on the aliphatic N1 in DMSO-d6, while in ethanol solutions most probably the quinazoline nitrogen atom N2 was also protonated.
Publisher
Trans Tech Publications, Ltd.
Subject
Mechanical Engineering,Mechanics of Materials,General Materials Science
Reference15 articles.
1. P.J. Medina, S. Goodin, Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases, Clin. Ther. 30 (2008) 1426-1447.
2. M.H. Nelson, C.R. Dolder, Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors, Ann. Pharmacother. 40 (2006) 261-269.
3. G. Tóth et al., Physicochemical characterization and cyclodextrin complexation of the anticancer drug lapatinib, J. Chem. 2017 (2017) 1-9.
4. Information from http://www.acdlabs.com/ilab/. ACD/Labs, Advanced Chemistry Development Inc., 90 Adelaide Street, West Toronto, Ontario, M5H3V9, Canada.
5. K. Ravikumar, B. Sridhar, N.J. Babu, A.K.S. Bhujanga Rao, R. Jyothiprasad, Tosylate salts of the anticancer drug lapatinib, Acta Crystallogr. Sect. C Cryst. Struct. Commun. 69 (2013) 1516-1523.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献